Literature DB >> 21412596

BCGiosis as a presenting feature of a child with chronic granulomatous disease.

Zahra Movahedi1, Sayna Norouzi, Setareh Mamishi, Nima Rezaei.   

Abstract

Bacillus Calmette Guerin (BCG) vaccine, which is administered to all newborns in some regions, could lead to serious complication ranging from local disease (known as BCGitis) to disseminated disease (BCGosis) in a group of patients with primary immunodeficiency diseases. We are reporting here a 3.5 year-old girl with a history of prolonged BCGitis, which developed to disseminated disease without any other special features. Immunological studies with nitro-blue tetrazolium test confirmed the diagnosis of chronic granulomatous disease in this patient. Chronic granulomatous disease should be considered in the list of differential diagnosis in all children with BCGosis, even in the absence of any other manifestations related to immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412596     DOI: 10.1016/s1413-8670(11)70146-5

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  10 in total

Review 1.  Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases.

Authors:  Sayna Norouzi; Asghar Aghamohammadi; Setareh Mamishi; Sergio D Rosenzweig; Nima Rezaei
Journal:  J Infect       Date:  2012-03-16       Impact factor: 6.072

Review 2.  Infectious Complications in Patients With Chronic Granulomatous Disease.

Authors:  Nicholas Bennett; Paul J Maglione; Benjamin L Wright; Christa Zerbe
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

3.  Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation.

Authors:  Christine Deffert; Michela G Schäppi; Jean-Claude Pache; Julien Cachat; Dominique Vesin; Ruth Bisig; Xiaojuan Ma Mulone; Tiina Kelkka; Rikard Holmdahl; Irene Garcia; Maria L Olleros; Karl-Heinz Krause
Journal:  PLoS Pathog       Date:  2014-09-04       Impact factor: 6.823

4.  Post-Vaccination Disseminated Bacillus Calmette Guerin Infection Among Children in Southern Iran.

Authors:  Mohammad Hasan Aelami; Abdolvahab Alborzi; Gholamreza Pouladfar; Bita Geramizadeh; Bahman Pourabbas; Jalal Mardaneh
Journal:  Jundishapur J Microbiol       Date:  2015-11-21       Impact factor: 0.747

5.  Granulomatous hepatitis as a rare complication of Bacillus Calmette-Guérin vaccination.

Authors:  Maryam Shoaran; Mehri Najafi; Rozita Jalilian; Nima Rezaei
Journal:  Ann Saudi Med       Date:  2013 Nov-Dec       Impact factor: 1.526

6.  Cutaneous Manifestations of Primary Immunodeficiency Diseases in Tunisian Children.

Authors:  Naouel Guirat Dhouib; Monia Ben Khaled; Monia Ouederni; Imen Ben-Mustapha; Ridha Kouki; Habib Besbes; Mohamed Ridha Barbouche; Fethi Mellouli; Mohamed Bejaoui
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

Review 7.  Challenges in the research and development of new human vaccines.

Authors:  T Barbosa; M Barral-Netto
Journal:  Braz J Med Biol Res       Date:  2013-02       Impact factor: 2.590

8.  Adverse effects of BCG vaccine 1173 P2 in Iran: A meta-analysis.

Authors:  Saied Mostaan; Bahador Yazdanpanah; Rasool Moukhah; Hamid Reza Hozouri; Manouchehr Rostami; Mohsen Khorashadizadeh; Javad Zerehsaz; Ramin Pirhajati Mahabadi; Arya Saadi; Hossein Khanahmad; Mohammad Pooya
Journal:  Adv Biomed Res       Date:  2016-06-08

9.  Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Authors:  Tara Rachakonda; Brian Kendall; Adam M Spivak; Jonathan Boltax
Journal:  Open Forum Infect Dis       Date:  2017-06-17       Impact factor: 3.835

10.  Pyoderma gangrenosum in a patient with chronic granulomatous disease: A case report.

Authors:  Sideris Nanoudis; Afroditi Tsona; Olga Tsachouridou; Petros Morfesis; Georgia Loli; Adamantini Georgiou; Pantelis Zebekakis; Symeon Metallidis
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.